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Interferon regulatory factor 5 (IRF5) regulates in-
flammatory M1 macrophage polarization, and dis-
ease-associated IRF5 genetic variants regulate
pattern-recognition-receptor (PRR)-induced cyto-
kines. PRR-stimulated macrophages and M1 macro-
phages exhibit enhanced glycolysis, a central medi-
ator of inflammation. We find that IRF5 is needed
for PRR-enhanced glycolysis in human macro-
phages and in mice in vivo. Upon stimulation of the
PRR nucleotide binding oligomerization domain con-
taining 2 (NOD2) in human macrophages, IRF5 binds
RIP2, IRAK1, and TRAF6. IRF5, in turn, is required for
optimal Akt2 activation, which increases expression
of glycolytic pathway genes and HIF1A as well as
pro-inflammatory cytokines and M1 polarization.
Furthermore, pro-inflammatory cytokines and glyco-
lytic pathways co-regulate each other. Rs2004640/
rs2280714 TT/TT IRF5 disease-risk-carrier cells
demonstrate increased IRF5 expression and in-
creased PRR-induced Akt2 activation, glycolysis,
pro-inflammatory cytokines, and M1 polarization
relative to GG/CC carrier macrophages. Our findings
identify that IRF5 disease-associated polymor-
phisms regulate diverse immunological and meta-
bolic outcomes and provide further insight into
mechanisms contributing to the increasingly recog-
nized important role for glycolysis in inflammation.INTRODUCTION
Proper pattern recognition receptor (PRR) responses to microbi-
al exposure are crucial in maintaining mucosal immune homeo-
stasis. Most studies show that interferon regulatory factor 5
(IRF5) is critical for optimal cytokine secretion upon stimulation
of a broad range of PRRs (Hedl and Abraham, 2012; Krausgruber
et al., 2011; Takaoka et al., 2005), although other studies show
more PRR selectivity (Bergstrøm et al., 2015). IRF5 polymor-
phisms resulting in increased IRF5 transcripts (Graham et al.,2442 Cell Reports 16, 2442–2455, August 30, 2016 ª 2016 The Autho
This is an open access article under the CC BY-NC-ND license (http://2006) are associated with multiple immune-mediated diseases,
including systemic lupus erythematosus (SLE), inflammatory
bowel disease (IBD), rheumatoid arthritis, Sjogren’s syndrome,
primary biliary cirrhosis, systemic sclerosis, and multiple scle-
rosis (Lazzari and Jefferies, 2014). Moreover, we found that
IRF5 disease-associated polymorphisms dramatically affect in-
ter-individual variance across the population in PRR-induced cy-
tokines in myeloid cells (Hedl and Abraham, 2012), thereby
raising the possibility that these polymorphisms may contribute
to differences in additional PRR-initiated outcomes. As a
transcription factor, IRF5 binds to cytokine gene promoters to
enhance PRR-initiated cytokine expression (Barnes et al.,
2002; Krausgruber et al., 2011; Saliba et al., 2014; Takaoka
et al., 2005). IRF5 also directly binds the adaptor molecule
MyD88 and the signaling intermediates IRAK1 and TRAF6 in
overexpression systems and mouse macrophages (Balkhi
et al., 2008; Inoue et al., 2014; Takaoka et al., 2005). How IRF5
regulates downstream pathways is incompletely understood.
We found that IRF5 is required for optimal PRR-initiated
mitogen-activated protein kinase (MAPK) and NF-kB activation
in human myeloid cells (Hedl and Abraham, 2012), although
IRF5 did not regulate these pathways in mouse B cells (Takaoka
et al., 2005). This could be due to differences in cell types but
also to differences in human and mouse inflammatory re-
sponses, which can be quite distinct (Seok et al., 2013), high-
lighting the importance of defining IRF5 regulation in primary
human cells. Consistent with its role in pathogen responses
(Pandey et al., 2009), most (Dalmas et al., 2015; Krausgruber
et al., 2011), but not all (Lacey et al., 2012) studies find that
IRF5 is required for the pro-inflammatory M1 macrophage
phenotype.
Interestingly, M1 macrophages show increased glycolytic flux
(Ganeshan and Chawla, 2014). Whether IRF5 is required for
glycolysis has not been examined. Glycolysis is a central medi-
ator of inflammatory outcomes, cell maturation, cytokine secre-
tion, and bacterial clearance inmyeloid cells (Cramer et al., 2003;
Everts et al., 2012; Krawczyk et al., 2010; O’Neill and Hardie,
2013) and regulates immune responses in vitro and in vivo in
additional cell types (O’Neill and Hardie, 2013). Following PRR
stimulation, glycolysis maintains mitochondrial ATP production
and cell viability (Cramer et al., 2003; Everts et al., 2012). Despite
the importance of IRF5 variants in human inflammatory diseases
and of IRF5 in cytokine secretion in PRR-stimulated myeloidr(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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cells, a number of questions remain unanswered. What are the
mechanisms through which IRF5 modulates human macro-
phage polarization? Given that IRF5 regulates PRR-initiated cy-
tokines and M1 polarization, and the critical role of enhanced
glycolysis under both these situations, does IRF5 regulate
glycolysis, and if so, through what mechanisms? As the risk
and non-risk alleles of these variants are commonly distributed
among the population, is M1 polarization and/or glycolysis regu-
lated in an IRF5 genotype-dependent manner?
In this study, in primary human monocyte-derived macro-
phages (MDMs), we found that IRF5 was essential for PRR-initi-
ated upregulation of glycolysis. We uncover that with PRR stim-
ulation, IRF5 leads to Akt2 activation, which results in enhanced
glycolysis and M1 polarization, and we dissect distinct up-
stream and downstream regulation of IRF5-dependent signaling
pathways. We further determine that IRF5-disease risk vari-
ants commonly expressed in the population regulate increased
inflammation through increased Akt2 activation, glycolysis, and
M1 polarization, thereby highlighting mechanisms by which
IRF5 regulates immune-mediated diseases.
RESULTS
PRR Stimulation Enhances Glycolysis through IRF5
Signaling
TLR stimulation induces glycolysis in human andmouse myeloid
cells (Cramer et al., 2003; Marsin et al., 2002; Rodrı´guez-Prados
et al., 2010), and glycolysis is essential for various immune out-
comes in vitro and in vivo (Cramer et al., 2003; Krawczyk et al.,
2010; O’Neill and Hardie, 2013). Given that IRF5 regulates
PRR-initiated cytokine secretion in humanmyeloid-derived cells,
we hypothesized that IRF5 would be necessary for PRR-induced
glycolysis in human macrophages. We first confirmed that
PRR stimulation increases glycolysis. We stimulated MDMs
with muramyl dipeptide (MDP), the minimal bacterial peptido-
glycan component that specifically activates NOD2, a PRR asso-
ciated with inflammatory bowel disease (IBD) (Abraham and
Cho, 2009), and found that lactate secretion, ameasure of glyco-
lytic flux, was increased (Figure 1A). Glucose uptake, which is
also associated with glycolysis, was similarly increased (Fig-
ure 1B). These outcomes were associated with a direct increase
in glycolytic pathway activity; NOD2 stimulation increased hexo-
kinase activity, the first step, and a rate-limiting glycolyticFigure 1. NOD2-Induced IRF5 and Akt2 Signaling Regulates Glycolytic
(A–C) Human MDMs (n = 4 donors) were transfected with IRF5 siRNA, then treate
Hexokinase activity. Mean + SEM.
(D) MDMs were transfected with the indicated siRNA. Left: following 15 min 100 m
serine phosphorylation was assessed by western blot. IRF5 and GAPDH expres
mean fluorescence intensity (MFI) values for IRF5 expression assessed by flow c
(E and F) MDMs (n = 8 for each panel) were transfected with the indicated siRNA a
withMFI values for phospho-kinase and summary graph with fold phospho-kinase
donor + SEM. Isotype controls (gray shading).
(G) MDMs (n = 4) were transfected with IRF5 or Akt2 siRNA and then treated with
activity). Mean + SEM.
(H and I) MDMs (n = 8) were transfected with IRF5 or Akt2 siRNA and then treated
scrambled siRNA-transfected cells for each donor + SEM. Similar results were
Significance relative to scrambled siRNA-transfected, MDP-treated cells, or as
yp < 1 3 104; yyp < 1 3 105.
2444 Cell Reports 16, 2442–2455, August 30, 2016enzyme (Figure 1C). We next effectively knocked down IRF5
(Figures 1D and S1A) and found that IRF5 deficiency led to
decreased lactate production, glucose uptake, and hexokinase
activity in NOD2-stimulated MDMs (Figures 1A–1C). Further-
more, following PRR stimulation of myeloid cell lines, IRF5 can
be phosphorylated and this modification is required for certain
downstream outcomes (Lopez-Pelaez et al., 2014; Ren et al.,
2014). MDP treatment led to IRF5 phosphorylation in a NOD2-
dependent manner as measured by a phospho-serine motif-de-
tecting antibody (Figure 1D). Taken together, IRF5 is required for
NOD2-induced glycolysis.
IRF5 Is Required for Akt2 Activation, and Akt2 Mediates
NOD2-Induced Glycolysis
Akt2 signaling regulates glycolysis in mouse hepatocytes (Pana-
syuk et al., 2012). To our knowledge, Akt2 contributions to
glycolysis have not been reported in humanMDMs.We therefore
asked if IRF5 regulates NOD2-induced Akt2 activation using a
phospho-Akt2-specific antibody. As a control, we measured
Akt1 phosphorylation. In mouse cells, Akt1 and Akt2 contribute
to M2 and M1 polarization, respectively (Arranz et al., 2012),
and we similarly found that Akt1 was required for optimal M2
polarization in human MDMs (data not shown). M1 macro-
phages show increased glycolysis, and M2 macrophages
show decreased glycolysis relative to non-polarized macro-
phages (Rodrı´guez-Prados et al., 2010). We first established
that NOD2 stimulation induced both Akt1 and Akt2 phosphoryla-
tion in MDMs (Figure 1E). We ensured that phospho-Akt1 and
phospho-Akt2 antibodies detected their specific targets using
a small interfering RNA (siRNA) approach (Figure 1E). We
confirmed reduced phospho-Akt1 and phospho-Akt2 with
knockdown through an independent approach (Figure S1B).
Interestingly, IRF5 knockdown decreased NOD2-induced Akt2
activation, but not Akt1 activation (Figure 1F). Neither NOD2
stimulation (Figure S1C) nor IRF5 knockdown affected total
Akt2 levels (Figure S1D). However, RIP2, an adaptor molecule
required for NOD2 signaling (Abraham and Cho, 2009), was
required for both NOD2-induced Akt1 and Akt2 activation (Fig-
ures 1F and S1E). Furthermore, Akt2 knockdown decreased
NOD2-induced glycolytic flux to similar levels as that observed
for IRF5 knockdown (Figure 1G). We confirmed these results
with additional independent siRNAs targeting IRF5 and Akt2
(Figures S1F and S1G). Moreover, IRF5 and Akt2 regulatedPathway Genes and Glycolysis in Human MDMs
d for 24 hr with 100 mg/ml MDP. (A) Lactate production. (B) Glucose uptake. (C)
g/ml MDP treatment, IRF5 was immunoprecipitated from cell lysates and IRF5
sion from total lysates served as loading controls. Right: summary graph with
ytometry + SEM (n = 4).
nd then treated for 15 min with 100 mg/ml MDP. Representative flow cytometry
induction compared to untreated, scrambled siRNA-transfected cells for each
100 mg/ml MDP for 24 hr (lactate production, glucose uptake, and hexokinase
with 100 mg/ml MDP for 4 hr. Fold mRNA expression compared to untreated,
seen in an additional n = 4 for (A–C and E–G) and n = 8 for (H and I). (G–I)
indicated. Tx, treatment; scr, scrambled. *p < 0.05; **p < 0.01; ***p < 0.001;
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Figure 2. IRF5-Deficient Mice Exhibit Decreased LPS-Induced
Glycolysis In Vivo
IRF5+/+, IRF5+/, or IRF5/ mice (n = 4–5/genotype) were injected intraperi-
toneally (i.p.) with 10 mg LPS for 24 hr. (A) Fold mRNA expression in liver and
spleen and (B) serum lactate levels (representative of two independent ex-
periments). Tx, treatment; *p < 0.05; **p < 0.01; ***p < 0.001.glycolysis downstream of additional PRRs in MDMs, including
TLR2, TLR3, and TLR4 (Figure S1H). We confirmed that each
PRR ligand specifically stimulated its respective receptor (Fig-
ure S1I); glycolysis remained intact in these sameMDMs treated
with a distinct PRR ligand (data not shown). Furthermore, IRF5
knockdown did not affect expression of the examined PRRs
and PRR knockdown did not alter IRF5 expression (Figures
S1J and S1K).
We next sought to definemechanisms through which IRF5 reg-
ulates NOD2-induced glycolysis. We examined genes in the
glycolysis pathway that convert glucose to pyruvate (Mun˜oz-
Pinedo et al., 2012) and found that NOD2 stimulation increased
hexokinase (HK1), triosephosphate isomerase (TPI), and phos-
phoglycerate mutase (PGAM), but not glucose-6-phosphate
isomerase (GPI), phosphofructokinase (PFKL), aldolase (ALDOA),
bisphosphoglycerate mutase (BPGM), phosphoglycerate kinase
(PGK), enolase (ENO1), and pyruvate kinase (PK) expression (Fig-
ure 1H). However, optimal expression of both induced and non-
induced genes mostly required IRF5 in NOD2-stimulated MDMs
(Figure 1H). Akt2 was similarly required for optimal expression ofthe glycolytic genes assessed (Figure 1H). IRF5 and Akt2 further
contributed toNOD2-inducedHIF1A expression (Figure 1I), which
also regulates glycolysis in macrophages (Cramer et al., 2003).
Taken together, IRF5 mediates Akt2 activation, and both mole-
cules are required for the optimal basal and NOD2-induced
expression of multiple glycolytic pathway genes and HIF1A.
IRF5 Regulates Glycolysis in Mice In Vivo
We next questioned whether IRF5 regulates PRR-induced
glycolysis in vivo. Upon lipopolysaccharide (LPS) injection, the
induction of HK1, PGAM, and HIF1A in liver and spleen (Fig-
ure 2A) and of serum lactate (Figure 2B) were significantly
decreased in IRF5-deficient mice relative to wild-type (WT) con-
trols. Therefore, IRF5 regulates glycolysis in mice in vivo.
Glycolytic Pathway Genes Regulate NOD2-Induced
Glycolysis and HIF1A Expression
We next asked whether the IRF5-dependent glycolytic-pathway
genes we had identified were, in fact, necessary for NOD2-
induced glycolysis in MDMs and questioned if these glycolytic
pathway genes co-regulated each other. We selected the subset
of genes whose expression was induced with NOD2 stimulation,
including HK1, TPI and PGAM (Figure 1H), and HIF1A (Figure 1I),
effectively knocked down their transcript and protein expression
(Figures S2A and S2B), and ensured the cells were viable (Fig-
ure S2C). We also ensured that HK1 knockdown diminished
hexokinase activity (data not shown). Each of these genes was
required for NOD2-induced glycolysis (Figure S2D). Importantly,
knockdown of each of the glycolytic genes decreased NOD2-
induced expression of the other glycolytic genes and of HIF1A
and vice versa (Figure S2A); the effect was more pronounced
following combined silencing of the three glycolytic genes
(Figure S2A). IRF5 and Akt2 expression was not affected by
knockdown of these glycolytic genes (Figure S2E). However,
knockdown of each of the glycolytic genes decreased Akt2 acti-
vation to varying degrees, while Akt1 activation remained un-
changed (Figure S2E), thereby demonstrating selectivity in the
regulation of downstream pathway activation and that Akt2 acti-
vation and glycolytic genes can co-regulate each other. Consis-
tently, the regulation of Akt activation by glycolysis has been
observed in cancer cells and overexpression systems (Pelicano
et al., 2006). HIF1A expression is regulated both following PRR
stimulation and under hypoxic conditions (Sica and Mantovani,
2012). We found that inducing hypoxia through two independent
approaches also induced Akt2 activation, glycolytic gene ex-
pression, and glycolysis in an IRF5-dependent manner in human
MDMs (Figures S2F–S2H); we ensured that the cells were viable
under these conditions (Figure S2I). Taken together, NOD2-
induced glycolytic pathway genes and HIF1A are required for
optimal NOD2-induced glycolysis in MDMs, and these genes
regulate the expression of each other.
IRF5Regulates the IncreasedGlycolysis Observed inM1
Macrophages, and Akt2 and MAPK/NF-kB Signaling
Show Distinct Regulation of Pro- and Anti-inflammatory
Cytokines
Given that M1 macrophages exhibit increased glycolysis
(Ganeshan and Chawla, 2014) and increased glycolytic geneCell Reports 16, 2442–2455, August 30, 2016 2445
expression (Galva´n-Pen˜a and O’Neill, 2014), and that IRF5 con-
tributes to M1 polarization (Krausgruber et al., 2011), we next
examined how IRF5 regulates glycolysis in distinct macrophage
subtypes. While macrophage polarization involves a broad
spectrum of phenotypes, we differentiated MDMs into M1 and
M2 phenotypes utilizing common conditions and confirmed
that they expressed appropriate markers as previously
described for human cells (Martinez et al., 2006) compared to
the non-polarized (M0) MDMs used in the studies above (Fig-
ure S3A). We confirmed that both IRF5 mRNA and protein
were upregulated in M1 macrophages relative to M0 macro-
phages (Figure 3A). Further, IRF5 expression and phosphoryla-
tion and Akt2 activation were increased following NOD2
stimulation (Figures 3A and 3B), with activation higher in M1
macrophages than that in undifferentiated macrophages (Fig-
ure 3B). In contrast, these outcomes were dramatically reduced
in M2 macrophages (Figures 3A and 3B). Compared to non-
polarized macrophages, M1 macrophages showed increased
glycolysis that was further increased with NOD2 stimulation (Fig-
ure 3C). The TLR4 ligand lipid A enhanced glycolysis through
IRF5 (Figure S1H). Consistently, the TLR4 ligand LPS used
for M1 differentiation activated Akt2 and enhanced glycolysis
in an IRF5-dependent manner (Figures S3B and S3C). Therefore,
impaired responses to LPS during M1 skewing conditions are
likely one mechanism contributing to the M1 polarization defect
in IRF5-deficient MDMs. Similar to non-polarized MDMs (Fig-
ure 1), optimal glycolysis in M1 macrophages required IRF5
and Akt2 (Figure 3C). Compared to M1 macrophages, glycolysis
was reduced inM2macrophages (Figure 3C). Expressing IRF5 in
M0 and M2 macrophages to the levels observed in M1 macro-
phages (Figure S3D) increased glycolysis to M1 levels (Fig-
ure S3E). Given the low IRF5 expression and phosphorylation
and low levels of glycolysis in M2 macrophages (Figures 3A–
3C), we focused our subsequent studies on M1 macrophages
and occasionally show non-polarizedM0macrophages for com-
parison in select measures. As Akt2 was necessary for NOD2-
induced glycolysis (Figures 1G and 3C) and Akt2 activation
was IRF5-dependent (Figure 1F), we restored Akt2 activation
to physiological levels in IRF5-deficient MDMs through transfec-
tion of constitutively active Akt2 (Figure S3F). This was sufficient
to restore diminished glycolysis in NOD2-stimulated IRF5-defi-
cient non-polarized and M1 macrophages (Figure 3D). Con-
sistent with the increased glycolysis in M1 macrophages (Fig-
ure 3C), glycolytic pathway genes were increased in M1
relative to M0 macrophages (Figure 3E). Similar to M0 macro-
phages, optimal NOD2-induced glycolytic gene expression in
M1 macrophages required both IRF5 and Akt2 (Figure 3E).
Consistent with the rescue of glycolysis, restoring Akt2 activa-
tion rescued NOD2-induced HK1, PGAM, TPI, and HIF1A
expression in IRF5-deficient M0 and M1 macrophages (Fig-
ure 3F). We verified the IRF5 contribution to M1 polarization by
assessingM1marker expression (Figure 3G) and NOD2-induced
pro-inflammatory cytokines (Figure 4A) under IRF5 knockdown
conditions. IRF5 was required for both pro- and anti-inflamma-
tory cytokine secretion in non-polarized human myeloid cells
upon NOD2 stimulation (Hedl and Abraham, 2012), which we
also confirm here (Figure 4A); IRF5 was similarly required for
optimal IFNa secretion (data not shown). Akt2 signaling was2446 Cell Reports 16, 2442–2455, August 30, 2016also required for M1 polarization (Figure 3G) and NOD2-induced
pro-inflammatory cytokines (Figure 4A). Restoring Akt2 activa-
tion rescuedM1macrophagemarkers in IRF5-deficient M1mac-
rophages (Figure 3H) and partially rescued pro-inflammatory cy-
tokines in M0 and M1 macrophages (Figure 4B), indicating that
additional pathways contribute to pro-inflammatory cytokines.
However, Akt2 was neither necessary nor sufficient for NOD2-
induced anti-inflammatory cytokine secretion in M0 macro-
phages (Figures 4A and 4B), indicating that IRF5-dependent
signaling pathways other than Akt2 are required for NOD2-
induced anti-inflammatory cytokines. Of note is that anti-inflam-
matory cytokines are already dramatically reduced in M1 relative
to non-polarized macrophages, such that anti-inflammatory cy-
tokines were not differentially regulated in the absence of IRF5 or
Akt2 in M1 macrophages (Figure 4A).
We previously showed that IRF5 activates PRR-induced
MAPK and NF-kB pathways (Hedl and Abraham, 2012).
We therefore questioned if the MAPK and/or NF-kB path-
ways might mediate NOD2-induced anti-inflammatory cyto-
kine secretion downstream of IRF5 given that IRF5-mediated
Akt2 activation did not. We further questioned if MAPK and/
or NF-kB pathways cooperate with Akt2 to more optimally
induce pro-inflammatory cytokines upon NOD2 stimulation.
Restoring MAPK and NF-kB activation in M0 macrophages
through expressing constructs resulting in constitutive activa-
tion of these pathways (Figures S3G and S3H) partially
rescued both pro-inflammatory and anti-inflammatory cyto-
kines (Figure 4B); rescue of NOD2-induced cytokines was
greater with restoring MAPK, NF-kB, and Akt2 activation in
combination (Figure 4B). Restoring all three pathways in com-
bination in M1 macrophages also more completely rescued
the high levels of NOD2-induced pro-inflammatory cytokines
(Figure 4B). Taken together, upon NOD2 stimulation, the
different signaling pathways downstream of IRF5 regulate
distinct outcomes; Akt2 activation is necessary for glycolysis,
M1 polarization and pro-inflammatory cytokine secretion, and
the MAPK and NF-kB pathways contribute to both pro- and
anti-inflammatory cytokine secretion.
The MAPK and NF-kB Pathways and Akt2 Pathway
Downstream of NOD2 Are Regulated by IRAK1/TRAF6
and BCAP Signaling, Respectively
Given the distinct immune outcomes we identified downstream
of the NOD2-induced, IRF5-dependent signaling pathways, we
next sought to more clearly define the upstream NOD2 signaling
intermediates that regulate the activation of the Akt2, MAPK, and
NF-kB pathways. We (Hedl et al., 2007) and others (Opitz et al.,
2004) have found that NOD2 activates IRAK1. IRAK1 activates
MAPK and NF-kB pathways downstream of PRRs (Kawai
and Akira, 2011; Opitz et al., 2004); it is unknown if IRAK1 regu-
lates NOD2-induced Akt2 signaling. We therefore successfully
knocked down IRAK1 and TRAF6 (Figures S4A and S4B), with
which IRAK1 forms a signaling complex (Kawai and Akira,
2011). Signaling by IRAK1 and TRAF6 was not required for
NOD2-induced Akt2 activation in MDMs (Figure 5A). In contrast,
IRAK1 and TRAF6 were required for NOD2-induced MAPK (Fig-
ure 5B) and NF-kB (Figure 5C) activation. BCAP is required for
PI3K activation through MyD88 in TLR-stimulated myeloid cells
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Figure 4. NOD2-InducedAkt2SignalingReg-
ulates Pro-inflammatory Cytokines, whereas
MAPK and NF-kB Signaling Regulates Both
Pro- and Anti-inflammatory Cytokines
MDMs or M1 macrophages were transfected with
(A) IRF5 or Akt2 siRNA (n = 4 donors), or (B) IRF5
siRNA ± empty vector (EV), constitutively active
Akt2 (ca-Akt2), a combination of constitutively
active ERK, p38 and JNK kinases (ca-MAPK), or
constitutively active NF-kB (ca-NF-kB) (n = 8) and
treated with 100 mg/ml MDP for 24 hr. Cytokine
secretion + SEM. Similar results were observed in
an additional n = 8.
(B) Significance relative to empty vector, IRF5
siRNA-transfected cells treated with MDP or as
indicated. Tx, treatment; scr, scrambled; ND, not
detected. yyp < 1 3 105.(Ni et al., 2012; Troutman et al., 2012). It is unknown if BCAP con-
tributes to NOD2 signaling, where signaling occurs through the
distinct adaptor molecule RIP2. We knocked down BCAP (Fig-
ures S4A and S4B) and found that in contrast to IRAK1
and TRAF6, BCAP was not required for NOD2-induced MAPK
and NF-kB pathway activation (Figures 5B and 5C) but was
required for Akt2 activation (Figure 5A). RIP2 and IRF5 were
required for NOD2-initiated signaling through all three pathways
(Figure 5). Therefore, upon NOD2 stimulation, activation of the
IRF5-dependent MAPK and NF-kB pathways and Akt2 pathway
are regulated by distinct branch points, with IRAK1/TRAF6 up-
stream of MAPK and NF-kB activation and BCAP upstream of
Akt2 activation.
The Transcription Factors SP1 and PU.1 Bind to
Glycolytic Gene Promoters
IRF5 is both a transcription factor and regulator of proximal
signaling. We therefore sought to dissect whether IRF5 could
regulate PRR-induced glycolytic outcomes by directly binding
to the promoters of the glycolytic genes and HIF1A, but
found this was not the case (Figure S4C); such binding has
similarly not been reported in studies examining the IRF5 cis-
trome (Saliba et al., 2014; Wang et al., 2013). NOD2 can also
activate IRF3, another transcription factor that can lead to
pro-inflammatory outcomes (Sabbah et al., 2009). IRF3 was
activated following NOD2 stimulation; however, IRF5 defi-
ciency did not affect IRF3 activation (Figure S4D). Further-Figure 3. NOD2-Induced Glycolysis in M1 Macrophages and M1 Polari
(A and B) MDMs were left non-polarized (M0) or were polarized to M1 or M2 macr
(A) Left: IRF5 mRNA (at 4 hr) (n = 4 donors). Right: protein expression by flow cyt
(numbers above bands represent relative band density normalized to treated M0 m
compared to untreated cells + SEM (n = 8). Significance relative to untreated M0
(C–H)MDMswere transfectedwith IRF5 or Akt2 siRNA ± empty vector (EV) or cons
for 24 hr. (C and D) Cells (n = 4) were left untreated or treated with 100 mg/ml MDP
M1 cells significance is compared to scrambled siRNA-transfected,MDP-treated
for 4 hr. Fold mRNA induction normalized to untreated, non-polarized, scrambled
of M1markers normalized to untreated, scrambled siRNA-transfectedM1macrop
siRNA-transfected cells treated with MDP or as indicated. Tx, treatment; scr, sc
2448 Cell Reports 16, 2442–2455, August 30, 2016more, unlike IRF5, IRF3 knockdown did not alter Akt2 activa-
tion or glycolysis following NOD2 stimulation (Figures S4E
and S4F).
We then hypothesized that Akt2-activated transcription fac-
tors might be regulating glycolytic gene expression; SP1 and
PU.1 can be activated downstream of Akt signaling (Pore
et al., 2004; Rieske and Pongubala, 2001), and we identified
putative binding sites for these transcription factors in the glyco-
lytic gene promoters based on JASPAR. SP1 and PU.1 binding
to the promoters of the glycolytic genes and HIF1A increased
upon NOD2 stimulation (Figure S4G). Furthermore, SP1 and
PU.1 knockdown (Figure S4H) demonstrated that these tran-
scription factors were required for optimal NOD2-induced
expression of glycolytic genes (Figure S4I) and glycolysis (Fig-
ure S4J). Taken together, rather than directly acting in its capac-
ity as a transcription factor, IRF5 likely regulates glycolysis
through modulation of Akt2 signaling, which leads to increased
binding of Akt-dependent transcription factors to glycolytic
gene promoters.
IKKb, RIP2, IRAK1, and TRAF6 Are Required for IRF5
Phosphorylation, andRIP2, IRAK1, andTRAF6Associate
with IRF5 following NOD2 Stimulation
We next sought to better define both the upstream mecha-
nisms regulating IRF5 phosphorylation and the mechanisms
through which IRF5 regulates proximal signaling. IKKb regu-
lates IRF5 phosphorylation in myeloid cell lines (Lopez-Pelaezzation Is IRF5- and Akt2-Dependent
ophages as in Experimental Procedures and then treated with 100 mg/ml MDP.
ometry (at 24 hr) (n = 8). Mean + SEM (B) Left: IRF5 phosphorylation at 15 min
acrophages). Right: fold phospho-Akt2 induction by flow cytometry at 15 min
macrophages or as indicated.
titutively active Akt2 (ca-Akt2), left non-polarized (M0), or polarized toM1 orM2
for 24 hr. Left: lactate production. Right: glucose uptake. Mean + SEM. (C) For
M1 cells, or as indicated. (E and F) Cells (n = 8) were treatedwith 100 mg/mlMDP
siRNA-transfected cells for each donor + SEM. (G and H) Fold mRNA induction
hages for each donor + SEM (n = 8). Significance relative to empty vector, IRF5
rambled. *p < 0.05; **p < 0.01; ***p < 0.001; yp < 1 3 104; yyp < 1 3 105.
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Figure 5. IRAK1/TRAF6 and BCAP Signaling
Show Distinct Regulation of NOD2-Induced
MAPK and NF-kB and Akt2 Pathways,
Respectively
MDMs (n = 8 donors) were transfected with the
indicated siRNA. Cells were then treated for 15min
with 100 mg/ml MDP and assessed for (A) Akt2, (B)
MAPK, or (C) NFkB pathway activation. Left:
representative flow with MFI values for phospho-
kinases. Right: fold phospho-kinase induction
compared to untreated, scrambled siRNA-trans-
fected cells for each donor +SEM. Significance
relative to MDP-treated, scrambled siRNA-trans-
fected cells. Isotype controls (gray shading). Tx,
treatment; scr, scrambled. yyp < 1 3 105.et al., 2014; Ren et al., 2014), and we found that both IKKb and
the NOD2-adaptor molecule RIP2 were required for NOD2-
mediated IRF5 serine phosphorylation in human MDMs (Fig-
ure 6A). Following phosphorylation, IRF5 can translocate into
the nucleus (Chang Foreman et al., 2012), and we observed
peak IRF5 nuclear translocation 4 hr after NOD2 stimulation
(Figure S5A). Consistent with regulating IRF5 phosphorylation,
IKKb and RIP2 were required for optimal NOD2-induced IRF5
nuclear translocation (Figure S5B). Furthermore, IRAK1 and
TRAF6, molecules downstream of NOD2 which regulated
IRF5-dependent MAPK and NF-kB pathway activation (Fig-
ure 5), were also required for IRF5 phosphorylation following
NOD2 stimulation (Figure 6A). Given our previous finding that
IRF5 is required for PRR-induced NF-kB activation in MDMs
(Hedl and Abraham, 2012), we asked if IKKb and IRF5
cross-regulate phosphorylation of each other. NOD2-induced
IKKb phosphorylation, in fact, depended on IRF5; as expected
IKKb phosphorylation also depended on NOD2, RIP2, IRAK1,
and TRAF6 with MDP treatment (Figure 6B). Taken together,
in addition to IKKb, RIP2, IRAK1, and TRAF6 are required for
NOD2-induced IRF5 phosphorylation, and IRF5, in turn, regu-
lates IKKb activation.Cell RepWe next sought to better define mech-
anisms through which IRF5 regulates
NOD2-induced signaling. IRF5 has been
found to associate with IRAK1 and
TRAF6 in overexpression systems and
mouse macrophages (Balkhi et al., 2008;
Inoue et al., 2014; Takaoka et al., 2005);
it is unclear if this is the case in primary
human macrophages. Furthermore, to
our knowledge, association of IRF5 and
RIP2 has not been reported. We found
that IRF5 associated with RIP2, IRAK1,
and TRAF6 in NOD2-stimulated human
MDMs (Figure 6C), consistent with the
requirement for each of these molecules
in regulating IRF5 phosphorylation
following NOD2 stimulation (Figure 6A).
Taken together, IRF5 associates with
PRR-signaling intermediates following
PRR stimulation, and these intermediatesare required for IRF5 phosphorylation and select IRF5-depen-
dent downstream outcomes.
Pro-inflammatory Cytokines and Glycolysis
Cross-regulate Each Other
Given that the levels of pro-inflammatory cytokines (Figure 4A)
and of glycolysis (Figure 3C) are high in M1 macrophages, we
investigated the relationship between these two PRR-induced
outcomes. Glycolytic gene expression and glycolysis were
induced by pro-inflammatory cytokines and IRF5 was required
for optimal regulation of these outcomes (Figures S6A and
S6B). Furthermore, blockade of NOD2-induced autocrine pro-in-
flammatory cytokines in both M0 and M1 macrophages resulted
in decreased glycolysis (Figure S6C), highlighting a role for auto-
crine pro-inflammatory cytokines in the enhanced glycolysis
observed with PRR stimulation. Moreover, knockdown of glyco-
lytic genes (Figure S6D) and hexokinase inhibition (data not
shown) reduced NOD2-induced cytokines, thereby establishing
a clear role for glycolysis in PRR-induced cytokine secretion.
Taken together, pro-inflammatory cytokines regulate glycolytic
outcomes in an IRF5-dependent manner, and pro-inflammatory
cytokines and glycolysis cross-regulate each other.orts 16, 2442–2455, August 30, 2016 2449
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Figure 6. RIP2, IRAK1, and TRAF6 Are Required for IRF5 Serine Phosphorylation and Associate with IRF5 in NOD2-Stimulated MDMs
(A) MDMs were transfected with the indicated siRNA and treated with 100 mg/ml MDP for 15 min. IRF5 was immunoprecipitated from cell lysates and IRF5 serine
phosphorylation was assessed by western blot. Total IRF5 and GAPDH expression from whole cell lysates (WCL) served as loading controls.
(B) MDMs (n = 8 donors) were transfected with the indicated siRNA. Cells were then treated for 15 min with 100 mg/ml MDP. Summary graph with fold phospho-
IKKb induction by flow cytometry compared to untreated, scrambled siRNA-transfected cells for each donor + SEM.
(C) MDMswere treated with 100 mg/mlMDP for 15min. IRF5 was immunoprecipitated from cell lysates and association of the indicated proteins was assessed by
western blot. Expression of the respective proteins in whole cell lysates served as a control. IgG isotypes were included as controls (data not shown). Tx,
treatment; scr, scrambled. yyp < 1 3 105.Macrophages from IRF5 Disease-Risk Variant Carriers
Show Increased IRF5 Protein Expression, Increased
NOD2-Induced Akt2 Activation and Glycolysis and
Increased M1 Polarization
Given the association of IRF5 polymorphisms with multiple
immune-mediated diseases (Graham et al., 2006) and the com-
mon distribution of the distinct IRF5 genotypes across the pop-
ulation, we sought to define how these variants regulate the
IRF5-dependent immune outcomes we defined in this study.
Disease-associated rs2004640/rs2280714 TT/TT carriers ex-
press increased IRF5 transcript levels relative to GG/CC
genotype carriers (Graham et al., 2006), and we previously found
that the rs2004640 T allele carriers express increased NOD2-
induced cytokines in a gene dose-dependent manner (Hedl
and Abraham, 2012). We ensured that following NOD2
stimulation, these risk carrier MDMs also expressed increased
IRF5 protein relative to non-risk carrier MDMs (Figure 7A);
IRF5 expression was higher in M1 macrophages (Figure 7A).
Heterozygotes showed an intermediate IRF5 expression (Fig-
ure 7A). In M1 macrophages from these disease-risk carriers,
NOD2-induced Akt2 activation and MAPK and NF-kB pathway
activation was increased relative to GG/CC genotype carriers
(Figure 7B). Consistent with the increased Akt2 activation
in MDMs from rs2004640/rs2280714 TT/TT disease risk carriers
(Figure 7B), NOD2-induced expression of glycolysis (Figure 7C),
glycolytic pathway genes (Figure 7D), and HIF1A (Figure 7D) was
increased inM1macrophages from rs2004640/rs2280714 TT/TT
disease risk carriers relative to GG/CC carriers. Furthermore,
M1 macrophages from IRF5 risk-allele carriers demonstrated
enhanced M1 polarization markers (Figure 7E). To establish
that the higher IRF5 expression in disease-risk carrier MDMs is
sufficient to regulate these various critical macrophages out-
comes, we transfected the lower IRF5-expressing non-risk car-
rier rs2004640/rs2280714 GG/CC NOD2-stimulated M1 macro-
phages with IRF5 to approximate the levels in rs2004640/
rs2280714 TT/TT risk carriers (Figure 7A). NOD2-induced Akt2
activation, glycolysis, glycolytic pathway gene expression, and
M1 polarization markers were increased under these conditions2450 Cell Reports 16, 2442–2455, August 30, 2016(Figure 7). Taken together, consistent with the increased IRF5
expression in MDMs from IRF5 disease-associated rs2004640/
rs2280714 TT/TT risk carriers, M1macrophages from these indi-
viduals show increased Akt2 activation, glycolytic pathway gene
expression, glycolysis, and M1 polarization.
DISCUSSION
We identify distinct IRF5-dependent signaling pathways and
mechanisms regulating diverse critical immune outcomes in
PRR-stimulated human macrophages. We establish that IRF5-
dependent activation of Akt2 signaling is required for expression
of glycolytic genes and HIF1A, and in turn, both basal and PRR-
induced glycolytic flux. We further find that IRF5 is required for
PRR-enhanced glycolysis in mice in vivo. Moreover, pro-inflam-
matory cytokines and PRR-induced autocrine cytokines regulate
glycolysis in an IRF5-dependent manner. IRF5-dependent Akt2
signaling is also necessary for M1 polarization, the enhanced
glycolysis in M1 macrophages, and the pro-inflammatory, but
not anti-inflammatory cytokine secretion in M0 and M1 macro-
phages. In contrast, IRF5-dependent MAPK and NF-kB path-
ways contribute to optimal NOD2-induced pro-inflammatory
and anti-inflammatory cytokines. The upstream regulation for
each of these pathways is also distinct, with BCAP upstream of
Akt2 and IRAK1/TRAF6 upstream of MAPK and NF-kB. More-
over, IRF5 associates with RIP2, IRAK1, and TRAF6 and each
of these molecules, in addition to IKKb, is required for NOD2-
induced IRF5 serine phosphorylation. Thus, in addition to its
role as a transcription factor, IRF5 associates with proximal
signaling molecules that regulate downstream outcomes as we
found in this study andas has beenobserved in additional reports
(Balkhi et al., 2008; Inoue et al., 2014; Takaoka et al., 2005).
Importantly, MDMs from rs2004640/rs2280714 TT/TT IRF5 dis-
ease risk carriers show increasedNOD2-inducedAkt2 activation,
glycolysis, M1 polarization, and M1-associated pro-inflamma-
tory cytokines relative to GG/CC carriers. Increasing IRF5 ex-
pression in the lower IRF5-expressing rs2004640/rs2280714
GG/CC non-risk allele carrier macrophages increases these
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Figure 7. Macrophages from rs2004640/rs2280714 TT/TT Disease-Risk Carriers Show Increased IRF5 Expression and Increased PRR-
Induced Akt2, MAPK, and NF-kB Pathway Activation, Glycolysis, and M1 Polarization
MDMs from rs2004640/rs2280714 TT/TT, GT/CT or GG/CC genotypes were transfected with empty vector (EV) or an IRF5-expressing vector as indicated for
24 hr.
(A) Cells (n = 9/genotype) were left non-polarized (M0) or polarized to M1 macrophages for 24 hr and then treated for 24 hr with 100 mg/ml MDP. Representative
and summarized flow cytometry data for IRF5 protein expression + SEM. Isotype controls (gray shading).
(B) M1macrophages (n = 9/genotype) were treated with 100 mg/ml MDP for 15min. Summarized flow cytometry data for fold phospho-Akt2, -ERK, -p38, -JNK, or
-IkBa normalized to untreated cells + SEM.
(C) M1 macrophages (n = 9/genotype) were treated with 100 mg/ml MDP for 24 hr. Lactate production and glucose uptake. Mean + SEM.
(D and E) M1 macrophages (n = 9/genotype) were treated with 100 mg/ml MDP for 4 hr. mRNA expression (change in CT values normalized to b-actin and
represented as a linear scale) + SEM. Tx, treatment. *p < 0.05; **p < 0.01; ***p < 0.001; yp < 1 3 104; yyp < 1 3 105.outcomes. Taken together, we identify IRF5 as a central regulator
of glycolysis and M1 polarization through Akt2 activation and
establish that IRF5 disease-risk carrier macrophages show an in-
crease in these inflammatory outcomes (Figure S7).Different Akt isoforms regulate distinct downstream out-
comes, including in metabolism, cell proliferation, motility (Hers
et al., 2011), and macrophage polarization (Arranz et al., 2012).
Therefore, it is crucial to understand how these isoforms areCell Reports 16, 2442–2455, August 30, 2016 2451
regulated. Until recently, studies utilized a phospho-antibody
recognizing a motif common to Akt1 and Akt2, such that differ-
ential activation was not generally dissected. Previously, we
used this common phospho-Akt antibody and found that with
IRF5 knockdown Akt signaling was intact (Hedl and Abraham,
2012). However, antibodies distinguishing Akt1 and Akt2 phos-
phorylation are now available and have been successfully used
by others (Jeffery et al., 2015). Using these selective antibodies,
we now identify that following NOD2 stimulation, while Akt1
phosphorylation remains intact following IRF5 knockdown,
Akt2 phosphorylation decreases (Figure 1). Selectivity in up-
stream Akt1 and Akt2 activation has not been well-defined;
PHLPP1 and PHLPP2 are one such example of molecules tar-
geting specific Akt isoforms (Brognard et al., 2007). Another
branch point downstream of NOD2 is the differential signaling in-
termediates required for activation of the Akt2 pathway and the
MAPK and NF-kB pathways (Figure 5). Furthermore, expression
of constructs leading to constitutive activation of these pathways
is sufficient to partially rescue select decreased outcomes in
NOD2-stimulated, IRF5-deficient human macrophages (Figures
3 and 4). Of note, is that in NOD2-stimulated human macro-
phages in which MAPKs and NF-kB are regulated physiologi-
cally, these pathways can play a non-redundant role in PRR-
induced cytokines, such that expression of constitutively active
signaling molecules may compensate for deficiencies in other
pathways. Another interesting observation is that IRAK1 and
TRAF6 are required for IRF5 phosphorylation (Figure 6A), but
are not required for Akt2 phosphorylation (Figure 5A). In contrast,
IRF5 is required for Akt2 phosphorylation (Figure 1F). This
suggests that some IRF5 downstream effects depend on IRF5
phosphorylation, at least as detected by the anti-phospho-
serine antibody utilized, while others do not. It is possible that
different post-translational IRF5 modifications may regulate
distinct IRF5-dependent functions. For example, IRF5 phos-
phorylation is required for nuclear translocation, transcription,
and apoptosis, but not for IRF5 ubiquitination (Chang Foreman
et al., 2012), such that IRF5 ubiquitination may regulate addi-
tional IRF5-dependent downstream events.
Although the association of glycolysis with inflammation in
myeloid cells and with inflammatory diseases in general has
been well established (Cramer et al., 2003; Krawczyk et al.,
2010), mechanisms regulating increased glycolysis following
PRR stimulation and in M1 macrophages are incompletely un-
derstood, particularly in primary human cells. Mechanisms
include increased TLR-induced association of HK2 with mito-
chondria in mouse DCs (Everts et al., 2012) and increased HK2
and lactate transporter expression in mouse macrophages
(Tan et al., 2015). We find that NOD2 stimulation increases
glycolysis by upregulating HK1, PGAM, TPI, and HIF1A in an
IRF5-dependent manner (Figure 1); IRF5 also regulates basal
expression of multiple additional glycolytic genes (Figure 1). To
our knowledge, PRR-mediated regulation of PGAM and TPI,
and NOD2- and Akt2- mediated regulation of glycolytic genes
in general has not been reported. Mutations in glycolytic genes
can regulate immune-mediated and infectious disease suscepti-
bility (Ayi et al., 2008). While the contribution of glycolysis to im-
mune-mediated diseases has beenmostly studied in the context
of T cells (Ganeshan and Chawla, 2014), studies also show an2452 Cell Reports 16, 2442–2455, August 30, 2016important role for glycolysis inmyeloid cells in immune-mediated
diseases. For example, loss of the glycolytic regulator HIF-1a
decreases experimental arthritis and cutaneous inflammation
in mice through regulating myeloid cell contributions to these
diseases (Cramer et al., 2003). We now find that HIF1A is regu-
lated in humanMDMs upon PRR stimulation in a manner depen-
dent on disease-associated IRF5 polymorphisms (Figure 7). We
further identify that these common IRF5 polymorphisms associ-
ated with multiple immune-mediated diseases can modulate
glycolysis in general.
This study identifies IRF5 as a critical link that integrates
PRR-induced andM1-enhanced glycolysis andM1 polarization
through Akt2 signaling, thereby highlighting key contributions
and mechanisms of IRF5 to immune outcomes. Furthermore,
we establish that macrophages from carriers of IRF5 variants
associated with increased IRF5 protein expression and multiple
immune-mediated diseases show increased PRR-induced
Akt2 activation, glycolysis, and M1 polarization. IRF5 polymor-
phisms are commonly distributed across the population and
contribute to susceptibility to multiple immune-mediated dis-
eases, making IRF5 a promising target for therapy of such dis-
eases. Our studies indicate that IRF5 might have additional
roles in multiple biological pathways regulated by glycolysis,
and we identify mechanisms and pathways differentially regu-
lated by IRF5 that could be targeted to decrease undesired
inflammation.
EXPERIMENTAL PROCEDURES
Patient Recruitment and Genotyping
Informed consent was obtained per protocol approved by the institutional
review board at Yale University. We recruited healthy individuals with no
personal or family history of autoimmune/inflammatory disease, including
psoriasis, SLE, rheumatoid arthritis, multiple sclerosis, type I diabetes melli-
tus, Crohn’s disease, and ulcerative colitis, or a history of HIV. Genotyping
was performed by TaqMan (Life Technologies) or Sequenom Platform
(Sequenom).
Primary Myeloid Cell Culture and MDM Polarization
Human peripheral blood mononuclear cells (PBMCs) were isolated from pe-
ripheral blood using Ficoll-Paque (GE Dharmacon). Monocytes were purified
from PBMCs by positive CD14 selection (Miltenyi Biotec) or adhesion (purity
was >98% by CD11c expression), and cultured in RPMI 1640 medium pH 7.3
containing 100 U/ml penicillin and 100 mg/ml streptomycin, 1 mM sodium
pyruvate, MEM non-essential amino acids, 10 mM HEPES (Thermo Fisher
Scientific), 10% fetal bovine serum, and M-CSF (10 ng/ml) (Shenandoah
Technology) for 7 days for MDM differentiation. In some studies, MDMs
were treated for 24 hr with 100 ng/ml LPS (Sigma-Aldrich) and 20 ng/ml
IFN-g (R&D Systems) (M1 polarization) or 20 ng/ml IL-4 (R&D Systems) (M2
polarization).
Mice
IRF5/ mice (C57BL/6) were generously provided by Dr. Betsy J. Barnes.
Mice were backcrossed with C57BL/6 mice to generate littermate controls.
Mice were maintained on autoclaved food in a specific pathogen-free facility.
Experiments were performed in agreement with the Yale University Institu-
tional Animal Care and Use Committee and NIH guidelines.
Myeloid Cell Stimulation
MDMs were treated with MDP (Bachem). Supernatants from 3 3 105 MDMs/
well in 24-well plates were assayed for TNF-a (clones MAb1 and MAb11), IL-8
(clones G265-5 and G265-8), IL-10 (clones JES3-9D7 and JES3-12G8)
(BDBiosciences), or IL-12p40 (clonesC8.3 andC8.6), IL-1Ra (cloneCRM17and
#13-7014-81) and IL-1b (clones CRM56 and CRM57) (eBioscience) by ELISA.
Lactate Production, Glucose Uptake, and Hexokinase Assays
Following stimulation of 5 3 104 MDMs/well in a 96-well plate, conversion of
lactate to pyruvate was measured as a change in NAD+ absorbance at
340 nm as per (Sekine et al., 1994), 2-deoxyglucose (VWR) uptake measured
as per (Yamamoto et al., 2006), and hexokinase activity per manufacturer’s in-
struction (Biovision).
Constructions and Transfection of siRNAs and DNA Vectors
A total of 100 nM scrambled or siGENOME SMARTpool siRNAs (a pool of
four distinct, commercially designed siRNA) against IRF5 (#M-011706-00),
Akt1 (#M-003000-03), Akt2 (#M-003001-02), NOD2 (#M-003464-01), IKKb
(#M00350303), IRAK-1 (#M-004760-03), TRAF6 (#M-004712-00), BCAP
(#M-016285-01), RIP2 (#M-003602-02), HK1 (#M-006820-01), TPI1 (#M-
009776-02), PGAM (#M-008883-01), orHIF1A (#M-004018-05) (GEDharmacon)
or 4 mg pMCL-MKK1 (R4F) (constitutively active ERK kinase) (Mansour et al.,
1994), 4 mg pSRa-3HA-JNKK2-JNK1-WT (constitutively active JNK) (Zheng
et al., 1999) (generous gifts from Dr. Ben Turk), 4 mg pcDNA3-Flag MKK6(glu)
(constitutively active p38 kinase) (Addgene plasmid 13518; kindly deposited by
Roger Davis) (Raingeaud et al., 1996), 2 mg IKK-2 S177D S181E (constitutively
active NF-kB) (Addgene plasmid 11105; kindly deposited by Anjana Rao) (Mer-
curio et al., 1997), 2 mg pcDNA3Myr HA Akt2 (constitutively active Akt2) (Addg-
ene plasmid 9016, kindly deposited by William Sellars), 2 mg IRF5 vector (Gene-
copoeia), or empty vector (a control vector without the gene of interest) were
transfected for 48hr (unlessotherwise indicated) intoMDMsusingAmaxanucle-
ofector technology (Amaxa). Transfection efficiency was >70%.
Protein Detection
Intracellular proteins were detected in permeabilized cells by flow cytometry
with Alexa Fluor 647, phycoerythrin, Alexa Fluor 488, or unlabeled antibodies
to phospho-ERK (D13.14.4E), phospho-p38 (3D7), phospho-JNK (G9), phos-
pho-IkBa (14D4) (Cell Signaling Technology), phospho-Akt1 (EP2109Y), phos-
pho-Akt2 (#ab110231) (Abcam), and IRF5 (1H6) (Novus). Briefly, 0.8–1 3 106
cells were fixed with Lyse/Fix Buffer (BD Biosciences) for 10min, permeabilized
for 1 hr with Perm Buffer III (BDBiosciences), washed, and then stained with the
indicated antibodies. RIP2 (25/RIG-G, BD Biosciences), TRAF6 (D21G3), and
IRAK-1 (D51G7) (Cell Signaling Technology) expression was detected by west-
ern blot and/or flow cytometry. GAPDH antibody (6C5, EMDMillipore) was used
to assess equal loading. For immunoprecipitation and western blot, 2–5 3 106
macrophages were lysed and lysates were centrifuged at 10,000 3 g for
10 min at 4C. For immunoprecipitation anti-IRF5 antibody (E1N9G, Cell
Signaling Technology)-bound protein A Sepharose (EMD Millipore) was incu-
bated with pre-cleared lysates at 4C overnight. Immunoprecipitates were run
on 10% SDS-PAGE gels and transferred to PVDF membrane (Bio-Rad). IRF5
serine phosphorylation was examined by incubation with an anti-phospho-
(Ser) R/KXXpSXP motif antibody (E2, Cell Signaling Technology). Signal was
detected by secondary anti-rabbit or anti-mouse IgG DyLight 680 and DyLight
800 antibodies (Thermo Fisher Scientific) with the Odyssey Imager (Li-COR Bio-
sciences). Densitometry was performed using Image J software (NIH).
mRNA Expression Analysis
Following stimulation, total RNAwas isolated from 0.5–13 106MDMs using Tri-
zol reagent (Thermo Fisher Scientific) according to manufacturer’s instructions.
RNA was treated with DNase (Thermo Fisher Scientific) and reverse transcribed
using first strand cDNA synthesis with Superscript III Reverse Transcriptase and
Oligo dT (Thermo Fisher Scientific). qPCR was performed using 100 ng RNA
equivalents/sample using All-In-One qPCR Mix (Genecopoeia) as in Hedl
et al. (2007) on the ABI Prism 7000 (Applied Biosystems). Sampleswere normal-
ized to b-actin. Primer sequences are available upon request.
Statistical Analysis
Significance was assessed using a two-tailed Student’s t test; p < 0.05 was
considered significant. Lines over adjacent bars indicate identical p values
for these bars.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2016.07.060.
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